RNS Number : 6749C
Genedrive PLC
11 February 2020

Director/PDMR Shareholding

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

genedrive plc (LSE: GDR) ("genedrive" or the "Company"), the near patient molecular diagnostics company, announces that Colleen Pythian, Director of Quality and Regulation and a PDMR, acquired 25,644 ordinary shares of 1.5p each ("Ordinary Shares") in the Company at a price of 9.70p per share today.

Following these purchases, Colleen Pythian's total beneficial interest is 25,644 Ordinary Shares, 0.07% of the issued share capital of the Company.

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

1.	***Details of the person discharging managerial responsibilities / person closely associated***	
a.	*Name*	*Colleen Pythian*
2.	***Reason for the notification***	
a.	*Position/status*	*Director of Quality & Regulation*
a.	*Initial notification /Amendment*	*Initial notification*
3.	***Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor***	
a.	*Name*	*genedrive plc*
b.	*LEI*	*213800ZYODIRZ87Y4K14*
4.	***Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted***	
a.	*Description of the Financial instrument, type of instrument Identification code*	*Ordinary shares of 1.5 pence each* *GB00B1VKB244*

<table>
<tr><td>b.</td><td>Nature of the transaction</td><td>Purchase</td></tr>
<tr><td>c.</td><td>Price(s) and volume(s)</td><td><table><tr><th>Price(s)</th><th>Volume(s)</th></tr><tr><td>9.70p</td><td>25,644</td></tr></table></td></tr>
<tr><td>d.</td><td>Aggregated information
· Aggregated volume
· Price</td><td>N/A</td></tr>
<tr><td>e.</td><td>Date of the transaction</td><td>2020-02-11</td></tr>
<tr><td>f.</td><td>Place of the transaction</td><td>London Stock Exchange, AIM</td></tr>
</table>

For further details please contact:

genedrive plc +44 (0)161 989 0245
David Budd: CEO / Matthew Fowler: CFO

Peel Hunt LLP (Nominated Adviser and Joint Broker) +44 (0)207 418 8900
James Steel / Oliver Jackson

Stanford Capital Partners Limited (Joint Broker) +44 (0)20 3815 8880
Patrick Claridge / John Howes

Walbrook PR Ltd (Media Relations & Investor Relations) +44 (0)20 7933 8780 or genedrive@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7876 741 001
Paul McManus / Anna Dunphy

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions

relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHEASAFFSKEEFA